Last Updated : April 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
|---|---|---|---|---|---|---|
| Arbesda RespiClick | fluticasone propionate / salmeterol xinafoate | Asthma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Soliqua | lixisenatide + insulin glargine | Diabetes mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Velphoro | sucroferric oxyhydroxide | Hyperphosphatemia, end-stage renal disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lenvima | Lenvatinib | Renal Cell Carcinoma (RCC) | Do not reimburse | Complete | ||
| Tagrisso | Osimertinib | Non-Small Cell Lung Cancer (NSCLC) (first line) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Steglatro | ertugliflozin | Diabetes mellitus, Type 2 | Do not reimburse | Complete | ||
| Segluromet | ertugliflozin and metformin hydrochloride | Diabetes mellitus, Type 2 | Do not reimburse | Complete | ||
| Cabometyx | Cabozantinib | Renal Cell Carcinoma (RCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xeljanz | tofacitinib | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Spinraza | Nusinersen | Spinal Muscular Atrophy | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 29, 2024